UK Triptan Switch Considered As MHRA Seeks Comment On Imitrex, Zomig
This article was originally published in The Tan Sheet
Executive Summary
UK consumers seeking a triptan for migraine treatment will be questioned by a pharmacist on their history of cardiovascular and cerebrovascular disease prior to purchase if sumatriptan or zolmitriptan are approved for nonprescription sale in the country
You may also be interested in...
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency